Indatuximab ravtansine is under investigation in clinical trial NCT01001442 (Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Indatuximab ravtansine. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Indatuximab ravtansine. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Indatuximab ravtansine. |
| Estrone | Estrone may increase the thrombogenic activities of Indatuximab ravtansine. |
| Estradiol | Estradiol may increase the thrombogenic activities of Indatuximab ravtansine. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Indatuximab ravtansine. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Indatuximab ravtansine. |
| Mestranol | Mestranol may increase the thrombogenic activities of Indatuximab ravtansine. |
| Estriol | Estriol may increase the thrombogenic activities of Indatuximab ravtansine. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Indatuximab ravtansine. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Indatuximab ravtansine. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Indatuximab ravtansine. |
| Tibolone | Tibolone may increase the thrombogenic activities of Indatuximab ravtansine. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Indatuximab ravtansine. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Indatuximab ravtansine. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Indatuximab ravtansine. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Indatuximab ravtansine. |
| Zeranol | Zeranol may increase the thrombogenic activities of Indatuximab ravtansine. |
| Equol | Equol may increase the thrombogenic activities of Indatuximab ravtansine. |
| Promestriene | Promestriene may increase the thrombogenic activities of Indatuximab ravtansine. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Indatuximab ravtansine. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Indatuximab ravtansine. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Indatuximab ravtansine. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Indatuximab ravtansine. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Indatuximab ravtansine. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Indatuximab ravtansine. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Indatuximab ravtansine. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Indatuximab ravtansine. |
| Formononetin | Formononetin may increase the thrombogenic activities of Indatuximab ravtansine. |
| Estetrol | Estetrol may increase the thrombogenic activities of Indatuximab ravtansine. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Indatuximab ravtansine. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Indatuximab ravtansine. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Indatuximab ravtansine. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Indatuximab ravtansine. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Indatuximab ravtansine. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Indatuximab ravtansine. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Indatuximab ravtansine. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Indatuximab ravtansine. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Indatuximab ravtansine. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Indatuximab ravtansine. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Indatuximab ravtansine. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Indatuximab ravtansine. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Indatuximab ravtansine. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Indatuximab ravtansine. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Indatuximab ravtansine. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Indatuximab ravtansine. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Indatuximab ravtansine. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Indatuximab ravtansine. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Indatuximab ravtansine. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Indatuximab ravtansine. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Indatuximab ravtansine. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Indatuximab ravtansine. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Indatuximab ravtansine. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Indatuximab ravtansine. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Indatuximab ravtansine. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Indatuximab ravtansine. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Indatuximab ravtansine. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Indatuximab ravtansine. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Indatuximab ravtansine. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Indatuximab ravtansine. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Indatuximab ravtansine. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Indatuximab ravtansine. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Indatuximab ravtansine. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Indatuximab ravtansine. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Indatuximab ravtansine. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Indatuximab ravtansine. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Indatuximab ravtansine. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Indatuximab ravtansine. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Indatuximab ravtansine. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Indatuximab ravtansine. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Indatuximab ravtansine. |
| Hepatitis B immune globulin | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Indatuximab ravtansine. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Indatuximab ravtansine. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Indatuximab ravtansine. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Indatuximab ravtansine. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Indatuximab ravtansine. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Indatuximab ravtansine. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Indatuximab ravtansine. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Indatuximab ravtansine. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Indatuximab ravtansine. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Indatuximab ravtansine. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Indatuximab ravtansine. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Indatuximab ravtansine. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Indatuximab ravtansine. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Indatuximab ravtansine. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Indatuximab ravtansine. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Indatuximab ravtansine. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Indatuximab ravtansine. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Indatuximab ravtansine. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Indatuximab ravtansine. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Indatuximab ravtansine. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Indatuximab ravtansine. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Indatuximab ravtansine. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Indatuximab ravtansine. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Indatuximab ravtansine. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Indatuximab ravtansine. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Indatuximab ravtansine. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Indatuximab ravtansine. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Indatuximab ravtansine. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Indatuximab ravtansine. |